Complete Listing of the Claims:

- 1 79. (canceled)
- 80. (currently amended) A method of treating a clinical condition associated with increased activity of <u>kallikrein</u>, <u>plasmin or Factor XIIa</u>, one or more serine proteases, comprising administering to a patient suffering from said clinical condition an effective amount of a pharmaceutical composition comprising <u>the following polypeptide</u>: a polypeptide selected from at least one of the following sequences:

(DD103) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVGGSAI (SEQ ID NO: 130) (DD104) EVVREVCSEOAETGPCRAMIYRWYFDVTEGKCAPFFYGGGGGRRNNFDTEEYCMAVGGSAI (SEO ID NO:131) (DD105) EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI (SEQ ID NO:132) (TW6182) EVVREVCSEOAETGPCRAMIHRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI (SEQ ID NO:134) (TW6194) EVVREVCSEOAETGPCRAMIERWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI (SEQ ID NO:135) (DD185) EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:171) (TW6165) EVVREVCSEQAETCPCRAAIWRWYFDVTECKCAPFFYGCCGGNRNNFDTEEYCMAVCGSAI (SEQ ID NO:172) (TW6166) EVVREVCSEQAETCPCRAAIYRWYFDVTECKCAPFFYCCCCGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:173) (BC028) EVVREVCSEOAETGPCRALIYRWYFDVTEGKCAPFFYGGGGGRRNNFDTEEYCMAVCGSAI (SEO-ID-NO:174) (TW6175) EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGGGGRNNFDTEEYCMAVCGSAI (SEQ-ID-NO:177) (TW6201)EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGCCGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:178) (TW6202)EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVGGSAI(SEQ-ID-NO:179) (DD114) EVVREVCSEQAETGPCRAAISRWYFDVTEGKCAPFFYGGCRGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:183) (TW6183)EVVREVCSEQAETCPCRAMHFRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:185) (TW6184)EVVREVCSEQAETGPCRAMHYRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYGMAVCGSAI(SEQ-ID-NO:186) (TW6185)EVVREVCSEQAETGPGRAMHWRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:187) (BG003)EVVREVCSEQAETGPCRAMLHRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:188) (TW6187)EVVREVCSEQAETCPCRAMIFRWYFDVTECKCAPFFYGGCYGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:190) (TW6188)EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:191) (TW6189)EVVREVCSEQAETGPCRAMIWRWYFDVTEGKCAPFFYGGGYGNRNNFDTEEYGMAVGGSAI(SEQ ID NO:192) (DD115)EVVREVCSEQAETCPCRGYITRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:194) (TW6176)EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI (SEQ-ID-NO:196) (TW6177)EVVREVCSEQAETGPCRALHFRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVGGSAI(SEO-ID-NO:197) (BG006)EVVREVCSEQAETGPCRAALFRWYFDVTECKCAPFFYCGCGCNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:198) (DD130)EVVREVCSEQAETCPCRALFTRWYFDVTECKCAPFFYCCCCGNRNNFDTEEYCMAVCCSAI(SEQ ID NO:199) (BG014)EVVREVCSEOAETGPCRALIWHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEO-ID-NO:204) (DD122)EVVREVCSEQAETCPCRALIFAWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:205) (BG015)EVVREVCSEQAETGPCRALIYHWYFDVTECKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:206) (BG020)EVVREVCSEOAETGPCRAAIHKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEO ID NO:207)

(BG022)EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMAVCGSAI(SEQ ID NO:208).

(BG024)EVVREVCSEQAETGPCRAAIYKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:210)

(DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCRGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:212)

(TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:213)

(BG029)EVVREVCSEQAEVGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:215)

(BG030)EVVREVCSEQAESGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:216)

(BG033)EVVREVCSEQAESGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMAVCGSAI(SEQ ID NO:217)

(BG034)EVVREVCSEQAESGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:218)

(BG040)EVVREVCSEQAEIGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:219)

(BG025)EVVREVCSEQAEIGPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:223)

81. (currently amended) A method for inhibiting activity of <u>kallikrein</u>, <u>plasmin or Factor</u>

<u>XIIa at least one serine protease</u> in a mammal comprising administering a therapeutically effective dose of a pharmaceutical composition, together with a pharmaceutically acceptable sterile vehicle, wherein said composition comprises <u>the following peptide</u>: a polypeptide selected from at least one of the following sequences:

(DD103) EVVREVCSEQAETGPCRAMIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI (SEQ ID NO:130) (DD104) EVVREVCSEQAETGPCRAMIYRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:131) (DD105) EVVREVCSEOAETGPCRAMIWRWYFDVTEGKCAPFFYGGCGGRRNNFDTEEYCMAVCGSAI (SEQ_ID_NO:132) (TW6182) EVVREVCSEQAETGPCRAMIHRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI (SEQ-ID-NO:134) (TW6194) EVVREVCSEQAETGPCRAMIERWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI (SEQ_ID_NO:135) (DD185) EVVREVCSEQAETCPCRAAIFRWYFDVTECKCAPFFYCCCGCNRNNFDTEEYCMAVCCSAI(SEQ ID NO:171) (TW6165) EVVREVCSEQAETGPCRAAIWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:172) (TW6166) EVVREVCSEOAETGPCRAAIYRWYFDVTECKCAPFFYGCCGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:173) (BC028) EVVREVCSEOAETCPCRALIYRWYFDVTECKCAPFFYCCCCCRRNNFDTEEYCMAVCCSAI(SEQ ID NO:174) (TW6175) EVVREVCSEQAETGPCRALIFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI (SEQ_ID_NO:177) (TW6201)EVVREVCSEQAETGPCRAGIYRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:178) (TW6202)EVVREVCSEQAETGPCRAGIWRWYFDVTEGKCAPFFYGGCGGRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:179) (DD114) EVVREVCSEQAETCPCRAAISRWYFDVTECKCAPFFYCCCRGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:183) (TW6183)EVVREVCSEQAETGPCRAMHFRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYGMAVGGSAI(SEQ ID NO:185) (TW6184)EVVREVCSEQAETGPGRAMHYRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVGGSAI(SEQ ID NO:186) (TW6185)EVVREVCSEQAETGPCRAMHWRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:187) (BG003)EVVREVCSEQAETGPCRAMLHRWYFDVTECKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:188) (TW6187)EVVREVCSEOAETGPCRAMIFRWYFDVTECKCAPFFYCCCYCNRNNFDTEEYCMAVCCSAI(SEQ-ID-NO:190) (TW6188)EVVREVCSEOAETGPCRAMIYRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:191) (TW6189)EVVREVCSEOAETGPCRAMIWRWYFDVTEGKCAPFFYGGGYGNRNNFDTEEYCMAVCGSAI(SEO-ID-NO:192) (DD115)EVVREVCSEQAETGPCRGYITRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:194)

(TW6176)EVVREVCSEQAETGPCRAAHFRWYFDVTEGKCAPFFYGGGGGRRNNFDTEEYCMAVGGSAI (SEQ-ID-NO: 196) (TW6177)EVVREVCSEQAETCPCRALHFRWYFDVTEGKCAPFFYGGGGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:197) (BG006)EVVREVCSEOAETGPCRAALFRWYFDVTEGKCAPFFYGGCGCNRNNFDTEEYCMAVCGSAI(SEQ_ID_NO:198) (DD130)EVVREVCSEQAETGPCRALFTRWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:199) (BG014)EVVREVCSEQAETGPCRALIWHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:204) (DD122)EVVREVCSEQAETGPCRALIFAWYFDVTECKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:205) (BG015)EVVREVCSEQAETCPCRALIYHWYFDVTECKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:206) (BG020)EVVREVCSEONETGPCRANIHKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEO-ID-NO:207) (BG022) EVVREVCSEQAETGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMAVCGSAI(SEQ ID NO: 208). (BG024)EVVREVCSEOAETGPCRALIYKWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEO ID NO: 210) (DD116)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCRGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:212) (TW6191)EVVREVCSEQAETGPCRAAIFRWYFDVTEGKCAPFFYGGCYGNRNNFDTEEYCMAVGGSAI(SEQ ID NO:213) (BG029)EVVREVCSEQAEVCPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYGMAVCGSAI(SEQ-ID-NO:215) (BG030)EVVREVCSEQAESCPCRALIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:216) (BG033)EVVREVCSEOAEVGPCRAAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEHCMAVCGSAI(SEO ID NO:217) (BG034)EVVREVCSEQAESCPCRAAIYHWYFDVTEGKCAPFFYGCCGGNRNNFDTEEYCMAVCGSAI(SEQ ID NO:218) (BG040)EVVREVCSEQAEICPCRALIYHWYFDVTECKCAPFFYCCCCCNRNNFDTEEYCMAVCCSAI(SEQ ID NO:219) (BG025)EVVREVCSEQAETCPCRGLIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:223) (BG026)EVVREVCSEQAETGPCRGAIYHWYFDVTEGKCAPFFYGGCGGNRNNFDTEEYCMAVCGSAI(SEQ-ID-NO:224)